• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Will First-in-Class IMAAVY Approval in Rare Anemia Reshape Johnson & Johnson’s (JNJ) Autoimmune Narrative?

    Simply Wall St·08/30/2026 01:29:49
    Listen to the news
    • On 24 August 2026, Johnson & Johnson received U.S. FDA approval for IMAAVY (nipocalimab-aahu) to treat warm autoimmune hemolytic anemia in patients aged 12 and older who are currently or were previously treated with corticosteroids.
    • This decision makes IMAAVY the first approved therapy for this rare, life‑threatening condition in steroid-treated patients, highlighting Johnson & Johnson’s push into targeted autoimmune treatments that spare broad immune suppression.
    • We’ll now examine how IMAAVY’s first‑in‑class approval for warm autoimmune hemolytic anemia fits into Johnson & Johnson’s broader investment narrative.

    This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality.

    Johnson & Johnson Investment Narrative Recap

    To own Johnson & Johnson today, you need to be comfortable with a diversified healthcare story where innovative medicines and MedTech offset loss of exclusivity and legal overhangs. IMAAVY’s first‑in‑class approval in warm autoimmune hemolytic anemia adds another niche immunology asset, but it does not meaningfully change the near term focus on replacing STELARA revenue or the ongoing uncertainty around talc litigation.

    The IMAAVY news sits alongside another key recent milestone: FDA authorization of the OTTAVA robotic surgery system for general surgery. Together, they underline how J&J is trying to balance new specialty drugs with higher value MedTech platforms that could matter more for long term earnings than any single rare disease indication.

    Yet despite these advances, the unresolved talc litigation still raises questions investors should be aware of about…

    Read the full narrative on Johnson & Johnson (it's free!)

    Johnson & Johnson’s narrative projects $120.5 billion revenue and $28.6 billion earnings by 2029.

    Uncover how Johnson & Johnson's forecasts yield a $270.59 fair value, in line with its current price.

    Exploring Other Perspectives

    JNJ 1-Year Stock Price Chart
    JNJ 1-Year Stock Price Chart

    The most optimistic analysts already assumed revenue could reach about US$125.7 billion and earnings US$29.6 billion by 2029, so IMAAVY’s approval might either support that bullish immunology story or prompt you to question whether such growth, and the reliance on a few blockbuster drugs, is realistic given the risks you just read about.

    Explore 8 other fair value estimates on Johnson & Johnson - why the stock might be worth as much as 36% more than the current price!

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Interested In Other Possibilities?

    The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.